Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.95
BMY's Cash-to-Debt is ranked lower than
63% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. BMY: 0.95 )
Ranked among companies with meaningful Cash-to-Debt only.
BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36  Med: 0.84 Max: 2.26
Current: 0.95
0.36
2.26
Equity-to-Asset 0.48
BMY's Equity-to-Asset is ranked lower than
69% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. BMY: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
BMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.43 Max: 0.52
Current: 0.48
0.33
0.52
Interest Coverage 27.72
BMY's Interest Coverage is ranked lower than
63% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.29 vs. BMY: 27.72 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 8.03  Med: 15.49 Max: 45.84
Current: 27.72
8.03
45.84
Piotroski F-Score: 6
Altman Z-Score: 5.89
Beneish M-Score: -2.22
WACC vs ROIC
8.60%
20.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 23.83
BMY's Operating Margin % is ranked higher than
86% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.86 vs. BMY: 23.83 )
Ranked among companies with meaningful Operating Margin % only.
BMY' s Operating Margin % Range Over the Past 10 Years
Min: 11.41  Med: 21.37 Max: 31.29
Current: 23.83
11.41
31.29
Net Margin % 22.94
BMY's Net Margin % is ranked higher than
91% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. BMY: 22.94 )
Ranked among companies with meaningful Net Margin % only.
BMY' s Net Margin % Range Over the Past 10 Years
Min: 9.45  Med: 15.78 Max: 56.42
Current: 22.94
9.45
56.42
ROE % 29.57
BMY's ROE % is ranked higher than
90% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.66 vs. BMY: 29.57 )
Ranked among companies with meaningful ROE % only.
BMY' s ROE % Range Over the Past 10 Years
Min: 10.75  Med: 20.69 Max: 78.36
Current: 29.57
10.75
78.36
ROA % 13.60
BMY's ROA % is ranked higher than
87% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.48 vs. BMY: 13.60 )
Ranked among companies with meaningful ROA % only.
BMY' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 9.18 Max: 35.08
Current: 13.6
4.78
35.08
ROC (Joel Greenblatt) % 130.89
BMY's ROC (Joel Greenblatt) % is ranked higher than
95% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.44 vs. BMY: 130.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 45.71  Med: 72.1 Max: 155.17
Current: 130.89
45.71
155.17
3-Year Revenue Growth Rate 5.50
BMY's 3-Year Revenue Growth Rate is ranked lower than
51% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. BMY: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.4  Med: 2.3 Max: 11.8
Current: 5.5
-8.4
11.8
3-Year EBITDA Growth Rate 18.40
BMY's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.70 vs. BMY: 18.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26  Med: -2.4 Max: 21.5
Current: 18.4
-26
21.5
3-Year EPS without NRI Growth Rate 19.80
BMY's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. BMY: 19.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: -4.8 Max: 30.7
Current: 19.8
-22.9
30.7
GuruFocus has detected 2 Warning Signs with Bristol-Myers Squibb Company $BMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMY's 10-Y Financials

Financials (Next Earnings Date: 2017-04-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BMY Guru Trades in Q1 2016

Ron Baron 112,848 sh (New)
Ken Fisher 636,060 sh (+371.85%)
Ray Dalio 86,845 sh (+22.58%)
Paul Tudor Jones 11,800 sh (+13.46%)
Pioneer Investments 233,487 sh (+8.31%)
Vanguard Health Care Fund 47,754,809 sh (+3.29%)
Murray Stahl 58,876 sh (+2.32%)
Mario Gabelli 654,005 sh (+2.29%)
Kahn Brothers 28,583 sh (+1.90%)
Jeff Auxier 4,993 sh (+1.01%)
RS Investment Management 526,000 sh (+0.95%)
Ronald Muhlenkamp 212,200 sh (+0.21%)
First Eagle Investment 12,943 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Louis Moore Bacon Sold Out
Ruane Cunniff Sold Out
Mairs and Power 285,918 sh (-0.40%)
Signature Select Canadian Fund 250,300 sh (-3.21%)
Dodge & Cox 73,458 sh (-5.16%)
T Rowe Price Equity Income Fund 4,031,100 sh (-10.82%)
Jeremy Grantham 4,100 sh (-24.07%)
John Burbank 1,374,032 sh (-29.83%)
Steven Cohen 532,100 sh (-57.91%)
Eaton Vance Worldwide Health Sciences Fund 1,029,700 sh (-22.75%)
» More
Q2 2016

BMY Guru Trades in Q2 2016

Keeley Asset Management Corp 2,960 sh (New)
Jim Simons 537,000 sh (New)
Ray Dalio 186,454 sh (+114.70%)
Paul Tudor Jones 13,800 sh (+16.95%)
Ken Fisher 648,107 sh (+1.89%)
Ron Baron 114,941 sh (+1.85%)
Eaton Vance Worldwide Health Sciences Fund 1,108,400 sh (+7.64%)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 4,993 sh (unchged)
John Burbank Sold Out
Mairs and Power 285,748 sh (-0.06%)
Murray Stahl 58,776 sh (-0.17%)
Dodge & Cox 72,158 sh (-1.77%)
Vanguard Health Care Fund 45,257,309 sh (-5.23%)
Mario Gabelli 619,627 sh (-5.26%)
Jeremy Grantham 3,800 sh (-7.32%)
First Eagle Investment 11,529 sh (-10.92%)
Steven Cohen 470,600 sh (-11.56%)
Ronald Muhlenkamp 181,340 sh (-14.54%)
Pioneer Investments 199,079 sh (-14.74%)
T Rowe Price Equity Income Fund 3,325,000 sh (-17.52%)
RS Investment Management 366,010 sh (-30.42%)
» More
Q3 2016

BMY Guru Trades in Q3 2016

Julian Robertson 400,800 sh (New)
Joel Greenblatt 87,321 sh (New)
Jim Simons 4,740,200 sh (+782.72%)
Paul Tudor Jones 116,887 sh (+747.01%)
Ray Dalio 390,577 sh (+109.48%)
Mairs and Power 330,822 sh (+15.77%)
Vanguard Health Care Fund 48,804,797 sh (+7.84%)
Ken Fisher 650,332 sh (+0.34%)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
First Eagle Investment 11,529 sh (unchged)
Jeremy Grantham Sold Out
Keeley Asset Management Corp Sold Out
Steven Cohen Sold Out
Dodge & Cox 71,958 sh (-0.28%)
Ronald Muhlenkamp 180,316 sh (-0.56%)
Murray Stahl 56,324 sh (-4.17%)
Jeff Auxier 4,693 sh (-6.01%)
T Rowe Price Equity Income Fund 3,100,000 sh (-6.77%)
Mario Gabelli 556,927 sh (-10.12%)
Signature Select Canadian Fund 160,450 sh (-35.90%)
Pioneer Investments 110,604 sh (-44.44%)
Ron Baron 47,479 sh (-58.69%)
Eaton Vance Worldwide Health Sciences Fund 955,887 sh (-13.76%)
» More
Q4 2016

BMY Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 3,060,280 sh (New)
Jeremy Grantham 3,500 sh (New)
Jana Partners 3,872,261 sh (New)
David Tepper 375,000 sh (New)
Dodge & Cox 22,532,761 sh (+31213.77%)
Vanguard Health Care Fund 51,340,697 sh (+5.20%)
Mairs and Power 340,822 sh (+3.02%)
T Rowe Price Equity Income Fund 3,125,000 sh (+0.81%)
Ken Fisher 653,730 sh (+0.52%)
Kahn Brothers 28,583 sh (unchged)
First Eagle Investment 11,529 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 4,693 sh (unchged)
Ray Dalio Sold Out
Julian Robertson Sold Out
Ron Baron Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 110,498 sh (-0.10%)
Ronald Muhlenkamp 178,961 sh (-0.75%)
Mario Gabelli 523,672 sh (-5.97%)
Murray Stahl 52,592 sh (-6.63%)
Paul Tudor Jones 23,777 sh (-79.66%)
Jim Simons 597,000 sh (-87.41%)
Eaton Vance Worldwide Health Sciences Fund 721,457 sh (-24.52%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1050.000.19$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:LLY, OTCPK:BAYRY, NYSE:ABBV, NYSE:AZN, OTCPK:GLAXF, NYSE:SNY, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:OPHLY, NYSE:MRK, NYSE:NVS, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH, NAS:HCM, OTCPK:BOIRF, NAS:AERI, OTCPK:HAWPF » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Bristol-Myers Squibb Co is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular and infectious diseases, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Guru Investment Theses on Bristol-Myers Squibb Company

Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company - Feb 13, 2017

Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players (AstraZeneca, the other) that will have an opportunity to ultimately come out on top given its strategy of combining two immune-therapeutics. We intend to follow the situation closely while looking for a more appropriate time to potentially get back into the investment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Dodge & Cox Comments on Bristol-Myers Squibb - Feb 01, 2017

Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis.



In 2016, one of Bristol-Myers’ lead immuno-oncology trials (CheckMate-026) failed and its stock price declined significantly. We think this is a short-term setback, and believe the company’s immuno-oncology business is particularly attractive with its strong pipeline of other drugs, significant growth potential, and reasonable valuation at 20 times forward earnings. After weighing the risks versus the long-term opportunities, we initiated a position in Bristol-Myers, which accounted for 1.3% of the Fund on December 31.





From Dodge & Cox's Stock Fund 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Co. - Oct 25, 2016

Bristol-Myers Squibb Company (NYSE:BMY) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb - May 23, 2016

After watching and following Bristol-Myers Squibb (NYSE:BMY) for the better part of the last three years we used the weakness in the stock created by the sell-off in the biotech sector to finally initiate a small to medium size position. Bristol specializes in small molecule drugs known as biologics, which are harder for the generic drug companies to replicate, and we are particularly excited about its lead immuno-oncology asset, Opdivo which has shown incredible promise in the treatment of lung cancer, while growing 10-20% month over month since its approval in 2015. Based on our belief in the effectiveness of the PD-1 class drugs, we think there is a high likelihood that Bristol will be able to gain approvals and expand the usage of Opdivo in other types of cancers (melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and could potentially change the paradigm of cancer’s treatment worldwide.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Company - May 06, 2016

After initiating a position in Bristol-Myers Squibb Company (NYSE:BMY), we increased our conviction in BMY’s stature as one of the premier names in all of biotech/pharma, deserving of its high multiple. Confidence comes from the performance of its lead immune-oncology asset, Opdivo that has captured 80–85% market share versus Merck’s competitive asset Keytruda, while growing 10–20% month over month. Given the frenetic pace of growth, we expect Opdivo to easily beat 2016’s $2.1 billion Consensus sales number. Looking past 2016, we expect this trend to continue as Bristol launches and/or expands usage of Opdivo in a variety of cancers (lung, melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and helps change the paradigm of cancer’s treatment worldwide.





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company - Mar 27, 2015

We increased our position in this biopharmaceutical company. We see its immuno-oncology franchise as a transformative driver in the years ahead and believe the market does not fully recognize the magnitude of the company’s potential in this area. Bristol-Myers Squibb (BMY) was the fund’s largest holding at the end of the period.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company Guru stock highlight
Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players Read more...
Dodge & Cox Comments on Bristol-Myers Squibb Guru stock highlight
Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis. Read more...
Stocks Reach Their 3-Year Low Prices Bristol-Myers Squibb and Express Scripts Holding reach historical low prices
Bristol-Myers Squibb Company (NYSE:BMY) reached $47.74 Read more...
Manning & Napier’s Top 3 New Holdings Firm invested in wide array of industries in the 4th quarter
Manning & Napier Advisors Inc. acquired 35 new holdings during the final quarter of 2016. The firm’s top three new holdings are Bristol-Myers Squibb Co. (NYSE:BMY), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Campbell Soup Co. (NYSE:CPB). Read more...
Investor Anticipating Bubble Julian Robertson Buys 2 Stocks in 3rd Quarter Tiger Management pioneer reports portfolio
Billionaire and pioneer of the long-short hedging strategy Julian Robertson (Trades, Portfolio) closed two stock transactions in the third quarter, his most frugal in exactly five years as he feared a market bubble fueled by years of loose monetary policy would culminate in chaos and groused in the media about the hedge fund business. Read more...
Baron Funds Comments on Bristol-Myers Squibb Co. Guru stock highlight
Bristol-Myers Squibb Company (NYSE:BMY) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt) Read more...
52-Week Company Lows Wells Fargo, Bristol-Myers, Nike, Target, Kroger, Whole Foods decline
According to GuruFocus, these stocks have reached their 52-week lows. Read more...
Baron Funds Comments on Bristol-Myers Squibb Guru stock highlight
After watching and following Bristol-Myers Squibb (NYSE:BMY) for the better part of the last three years we used the weakness in the stock created by the sell-off in the biotech sector to finally initiate a small to medium size position. Bristol specializes in small molecule drugs known as biologics, which are harder for the generic drug companies to replicate, and we are particularly excited about its lead immuno-oncology asset, Opdivo which has shown incredible promise in the treatment of lung cancer, while growing 10-20% month over month since its approval in 2015. Based on our belief in the effectiveness of the PD-1 class drugs, we think there is a high likelihood that Bristol will be able to gain approvals and expand the usage of Opdivo in other types of cancers (melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and could potentially change the paradigm of cancer’s treatment worldwide. Read more...
Baron Funds Comments on Bristol-Myers Squibb Company Guru stock highlight
After initiating a position in Bristol-Myers Squibb Company (NYSE:BMY), we increased our conviction in BMY’s stature as one of the premier names in all of biotech/pharma, deserving of its high multiple. Confidence comes from the performance of its lead immune-oncology asset, Opdivo that has captured 80–85% market share versus Merck’s competitive asset Keytruda, while growing 10–20% month over month. Given the frenetic pace of growth, we expect Opdivo to easily beat 2016’s $2.1 billion Consensus sales number. Looking past 2016, we expect this trend to continue as Bristol launches and/or expands usage of Opdivo in a variety of cancers (lung, melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and helps change the paradigm of cancer’s treatment worldwide. Read more...

Ratios

vs
industry
vs
history
PE Ratio 21.09
BMY's PE Ratio is ranked higher than
65% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.50 vs. BMY: 21.09 )
Ranked among companies with meaningful PE Ratio only.
BMY' s PE Ratio Range Over the Past 10 Years
Min: 4.09  Med: 22.13 Max: 77.61
Current: 21.09
4.09
77.61
Forward PE Ratio 19.42
BMY's Forward PE Ratio is ranked lower than
62% of the 89 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.46 vs. BMY: 19.42 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.09
BMY's PE Ratio without NRI is ranked higher than
66% of the 581 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. BMY: 21.09 )
Ranked among companies with meaningful PE Ratio without NRI only.
BMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.33  Med: 23.6 Max: 77.61
Current: 21.09
12.33
77.61
Price-to-Owner-Earnings 34.74
BMY's Price-to-Owner-Earnings is ranked lower than
52% of the 296 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.92 vs. BMY: 34.74 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.57  Med: 27.32 Max: 842.8
Current: 34.74
3.57
842.8
PB Ratio 5.77
BMY's PB Ratio is ranked lower than
77% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.93 vs. BMY: 5.77 )
Ranked among companies with meaningful PB Ratio only.
BMY' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 4.35 Max: 8.51
Current: 5.77
2.46
8.51
PS Ratio 4.83
BMY's PS Ratio is ranked lower than
67% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. BMY: 4.83 )
Ranked among companies with meaningful PS Ratio only.
BMY' s PS Ratio Range Over the Past 10 Years
Min: 1.63  Med: 2.99 Max: 7.24
Current: 4.83
1.63
7.24
Price-to-Free-Cash-Flow 57.44
BMY's Price-to-Free-Cash-Flow is ranked lower than
77% of the 228 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.42 vs. BMY: 57.44 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.45  Med: 19.79 Max: 926.83
Current: 57.44
7.45
926.83
Price-to-Operating-Cash-Flow 32.93
BMY's Price-to-Operating-Cash-Flow is ranked lower than
74% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.18 vs. BMY: 32.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.96  Med: 14.75 Max: 147.61
Current: 32.93
6.96
147.61
EV-to-EBIT 15.23
BMY's EV-to-EBIT is ranked higher than
63% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. BMY: 15.23 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 15.25 Max: 126.7
Current: 15.23
6.2
126.7
EV-to-EBITDA 14.33
BMY's EV-to-EBITDA is ranked higher than
55% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.30 vs. BMY: 14.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 13.55 Max: 57.3
Current: 14.33
5.5
57.3
Shiller PE Ratio 25.34
BMY's Shiller PE Ratio is ranked higher than
77% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.64 vs. BMY: 25.34 )
Ranked among companies with meaningful Shiller PE Ratio only.
BMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.76  Med: 16.91 Max: 36.36
Current: 25.34
10.76
36.36
Current Ratio 1.55
BMY's Current Ratio is ranked lower than
71% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. BMY: 1.55 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.57 Max: 2.21
Current: 1.55
1.15
2.21
Quick Ratio 1.41
BMY's Quick Ratio is ranked lower than
61% of the 613 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.73 vs. BMY: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.36 Max: 1.99
Current: 1.41
0.95
1.99
Days Inventory 99.14
BMY's Days Inventory is ranked higher than
59% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. BMY: 99.14 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 84.37  Med: 122.43 Max: 141.93
Current: 99.14
84.37
141.93
Days Sales Outstanding 70.91
BMY's Days Sales Outstanding is ranked higher than
56% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.23 vs. BMY: 70.91 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.65 Max: 79.99
Current: 70.91
35.38
79.99
Days Payable 122.80
BMY's Days Payable is ranked higher than
75% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. BMY: 122.80 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 84.65  Med: 141.65 Max: 230.86
Current: 122.8
84.65
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.74
BMY's Dividend Yield % is ranked higher than
75% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.24 vs. BMY: 2.74 )
Ranked among companies with meaningful Dividend Yield % only.
BMY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 4.05 Max: 7.07
Current: 2.74
1.99
7.07
Dividend Payout Ratio 0.58
BMY's Dividend Payout Ratio is ranked lower than
73% of the 402 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. BMY: 0.58 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.92 Max: 1.6
Current: 0.58
0.58
1.6
3-Year Dividend Growth Rate 2.80
BMY's 3-Year Dividend Growth Rate is ranked lower than
66% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. BMY: 2.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3 Max: 11.4
Current: 2.8
0
11.4
Forward Dividend Yield % 2.79
BMY's Forward Dividend Yield % is ranked higher than
75% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.64 vs. BMY: 2.79 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.15
BMY's 5-Year Yield-on-Cost % is ranked higher than
69% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.91 vs. BMY: 3.15 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.28  Med: 4.65 Max: 8.12
Current: 3.15
2.28
8.12
3-Year Average Share Buyback Ratio -0.60
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 441 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. BMY: -0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: -0.6
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 11.80
BMY's Price-to-Tangible-Book is ranked lower than
86% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. BMY: 11.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.33  Med: 15.99 Max: 53.46
Current: 11.8
6.33
53.46
Price-to-Intrinsic-Value-Projected-FCF 2.17
BMY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. BMY: 2.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.68 Max: 4.14
Current: 2.17
1.15
4.14
Price-to-Median-PS-Value 1.62
BMY's Price-to-Median-PS-Value is ranked lower than
73% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. BMY: 1.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.79  Med: 1.03 Max: 2.88
Current: 1.62
0.79
2.88
Price-to-Graham-Number 3.33
BMY's Price-to-Graham-Number is ranked lower than
72% of the 423 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.21 vs. BMY: 3.33 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.04  Med: 4.52 Max: 11.36
Current: 3.33
2.04
11.36
Earnings Yield (Greenblatt) % 6.57
BMY's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. BMY: 6.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.55 Max: 16.1
Current: 6.57
0.8
16.1
Forward Rate of Return (Yacktman) % -1.13
BMY's Forward Rate of Return (Yacktman) % is ranked lower than
70% of the 364 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.76 vs. BMY: -1.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.1  Med: 3.1 Max: 26.7
Current: -1.13
-15.1
26.7

More Statistics

Revenue (TTM) (Mil) $19,427
EPS (TTM) $ 2.65
Beta0.89
Short Percentage of Float2.13%
52-Week Range $46.01 - 77.12
Shares Outstanding (Mil)1,647.50

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19,957 20,866 20,708
EPS ($) 2.86 3.10 2.97
EPS without NRI ($) 2.86 3.10 2.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
19.42%
Dividends per Share ($) 1.71 1.61 1.66
» More Articles for BMY

Headlines

Articles On GuruFocus.com
Weekly Top Insider Buys Highlight for the Week of March 3 Mar 04 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company Feb 13 2017 
Dodge & Cox Comments on Bristol-Myers Squibb Feb 01 2017 
Dodge & Cox's Stock Fund 4th Quarter Letter to Shareholders Feb 01 2017 
Is Bristol-Meyers a Buy After 39% Price Decline? Jan 29 2017 
Stocks Reach Their 3-Year Low Prices Jan 28 2017 
Manning & Napier’s Top 3 New Holdings Jan 26 2017 
52-Week Company Lows Jan 26 2017 
Biotech Stocks to Watch After Senate Drug Report Dec 27 2016 

More From Other Websites
8:31 am Bristol-Myers confirms the CHMP has recommended the approval of Opdivo as monotherapy for... Mar 25 2017
Bristol-Myers Opdivo Gets CHMP Nod for Head, Neck Cancer Mar 24 2017
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the... Mar 24 2017
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved Mar 24 2017
Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment Mar 24 2017
BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers Mar 23 2017
Dow's Merck Swipes Immuno-Oncology Share From Heavyweight Rivals Mar 22 2017
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal Mar 21 2017
Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal Mar 20 2017
Here’s Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending Mar 20 2017
Bristol-Myers, CytomX Extend Cancer Drug Pact Mar 20 2017
A small drug company that's trying to make cancer treatments safer just received a $3.8 billion... Mar 20 2017
Monday’s Top Biopharma Movers Mar 20 2017
Stocks Edge Lower At The Open; Sprouts Up Again On Merger Talk Mar 20 2017
CytomX Soars on Bristol-Myers Partnership Mar 20 2017
Changes in Bristol-Myers Squibb’s Profitability in 2016 Mar 20 2017
How BMY’s Neuroscience, Immunoscience Segments Performed in 2016 Mar 20 2017
CytomX's stock rockets after expanding Bristol-Myers collaboration Mar 20 2017
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™... Mar 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)